Program
milvexian
Also written as “BMS-986177”, “Milvexian” and “JNJ-70033093”.
Its studies are mostly in Thrombosis · Ischemic Stroke · Atrial Fibrillation · Acute Coronary Syndrome · Stroke, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 140 open or running | phase 2since Dec 20, 2016 | Nov 17, 2015 | none ahead |
| Johnson & Johnson | 112 open or running | phase 3since Jan 19, 2023 | Mar 25, 2019 | Dec 8, 2026phase 3 · NCT05757869 |
- Named in Bristol-Myers Squibb’s own pipeline as
milvexian
, phase 3, as of Oct 29, 2026 (source). - Named in Johnson & Johnson’s own pipeline as
milvexian
, phase 3, as of Oct 13, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 10 studies since Nov 17, 2015.
- Oct 4, 2018Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT03698513 · 113 enrolled · United States
- Nov 13, 2018Phase 2 study in Ischemic StrokeBristol-Myers Squibb · NCT03766581 · 2,366 enrolled · United States, Argentina, Australia and more
- Mar 25, 2019Johnson & Johnson's first study: phase 2 study in Arthroplasty, Replacement, KneeNew to Johnson & JohnsonJohnson & Johnson · NCT03891524 · 1,242 enrolled · United States, Argentina, Belgium and more
- May 2, 2019Phase 1 study in ThrombosisBristol-Myers Squibb · NCT03939702 · 9 enrolled · United States
- Dec 18, 2019Phase 1 study in HealthyJohnson & Johnson · NCT04206488 · 30 enrolled · Belgium
- Jan 8, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04223349 · 66 enrolled · United States
- May 12, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04388501 · 23 enrolled · Belgium
- Jun 25, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04448964 · 24 enrolled · Belgium
- Sep 11, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04569695 · 40 enrolled · China
- Apr 12, 2021Phase 1 study in HealthyJohnson & Johnson · NCT04844424 · 115 enrolled · United States
- Jul 7, 2021Phase 1 study in Healthy VolunteersBristol-Myers Squibb · NCT04965389 · 17 enrolled · United Kingdom
- Jan 19, 2023Phase 3 study in Ischemic StrokeJohnson & Johnson · NCT05702034 · 12,523 enrolled · United States, Argentina, Australia and more
- Jan 23, 2023Phase 1 study in Healthy FemaleJohnson & Johnson · NCT05706753 · 20 enrolled · Belgium
- Feb 23, 20232 phase 3 studiesJohnson & Johnson · NCT05754957, NCT05757869
Ahead
- Dec 8, 2026Primary completion: phase 3 study in Atrial FibrillationJohnson & Johnson · NCT05757869
TargetBeta
“A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation”study text, read by Claude · the study
Other programs on F11
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| abelacimab | anthos-therapeutics-inc | phase 3 | 8 |
| SHR-2004 | Jiangsu HengRui Medicine | phase 3 | 5 |
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05757869Atrial Fibrillation · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Dec 8, 2026 | 20,284 |
| NCT05754957Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Completed | Johnson & Johnson | Feb 6, 2026 | 14,194 |
| NCT05706753Healthy Female · Belgium | 1 | Completed | Johnson & Johnson | Jul 20, 2023 | 20 |
| NCT05702034Ischemic Stroke · United States, Argentina, Australia and more | 3 | Active, not recruiting | Johnson & Johnson | Oct 15, 2026 | 12,523 |
| NCT04965389Healthy Volunteers · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Aug 22, 2021 | 17 |
| NCT04844424Healthy · United States | 1 | Completed | Johnson & Johnson | May 6, 2022 | 115 |
| NCT04569695Healthy · China | 1 | Completed | Johnson & Johnson | Dec 4, 2021 | 40 |
| NCT04448964Healthy · Belgium | 1 | Completed | Johnson & Johnson | Nov 14, 2020 | 24 |
| NCT04388501Healthy · Belgium | 1 | Completed | Johnson & Johnson | Oct 25, 2021 | 23 |
| NCT04223349Healthy · United States | 1 | Completed | Johnson & Johnson | Apr 8, 2020 | 66 |
| NCT04206488Healthy · Belgium | 1 | Completed | Johnson & Johnson | Jun 9, 2021 | 30 |
| NCT03939702Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Jul 11, 2019 | 9 |
| NCT03891524Arthroplasty, Replacement, Knee · United States, Argentina, Belgium and more | 2 | Completed | Johnson & Johnson | Apr 6, 2021 | 1,242 |
| NCT03766581Ischemic Stroke · United States, Argentina, Australia and more | 2 | Completed | Bristol-Myers Squibb | Mar 31, 2022 | 2,366 |
| NCT03698513Healthy Volunteers · United States | 1 | Completed | Bristol-Myers Squibb | Feb 19, 2019 | 113 |
| NCT03362437Thrombosis · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Dec 28, 2017 | 12 |
| NCT03341390Stroke · United States | 1 | Completed | Bristol-Myers Squibb | Nov 16, 2017 | 20 |
| NCT03224260Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Nov 7, 2017 | 33 |
| NCT03196206Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Mar 4, 2018 | 24 |
| NCT03000673Antithrombotic · United States | 2 | Completed | Bristol-Myers Squibb | Oct 23, 2017 | 32 |
| NCT02982707Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Sep 28, 2018 | 26 |
| NCT02959060Thrombosis | 1 | Completed | Bristol-Myers Squibb | Dec 2016 | 16 |
| NCT02902679Thrombosis · United States | 1 | Completed | Bristol-Myers Squibb | Jun 2017 | 6 |
| NCT02807909Thrombosis | 1 | Completed | Bristol-Myers Squibb | Aug 2016 | 28 |
| NCT02608970Thrombosis · Belgium | 1 | Completed | Bristol-Myers Squibb | Jul 23, 2017 | 104 |
How it is read
Names in the registry
- “BMS-986177”, 14 entries
- “Milvexian”, 6 entries
- “JNJ-70033093”, 4 entries
- “JNJ-70033093 25 mg”, 1 entry
- “JNJ-70033093 50 mg”, 1 entry
Conditions, from the studies’ own filings
- Thrombosis, 9 studies
- Ischemic Stroke, 2 studies
- Atrial Fibrillation, 1 study
- Acute Coronary Syndrome, 1 study
- Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.